Dynavax Technologies Corporation (DVAX) reported quarterly earnings results on Friday, Aug-5-2016. The company reported $-0.75 earnings per share for the quarter, missing the analyst consensus estimate by $-0.06. Analysts had a consensus of $-0.69. The company posted revenue of $2.65 million in the period, compared to analysts expectations of $1.58 million. The company’s revenue was up 70.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.80 EPS.
Dynavax Technologies Corporation opened for trading at $15.69 and hit $16.15 on the upside on Thursday, eventually ending the session at $15.95, with a gain of 2.51% or 0.39 points. The heightened volatility saw the trading volume jump to 6,07,136 shares. Company has a market cap of $614 M.
In a different news, on Jun 30, 2016, Robert Janssen (Vice President) purchased 1,452 shares at $13.68 per share price. According to the SEC, on May 23, 2016, Eddie Gray (CEO) purchased 2,750 shares at $15.57 per share price.
Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are organized under three areas of focus: vaccine adjuvants cancer immunotherapy and autoimmune and inflammatory diseases. The Companys pipeline of product candidates includes HEPLISAV-B an investigational adult hepatitis B vaccine is in Phase III clinical trials; SD-101 a cancer immunotherapy candidate is in Phase I/II clinical trials; AZD1419 a candidate drug for asthma is in Phase II clinical trials planning; DV1179 is an inhibitor of TLR 7 and TLR 9 for autoimmune and inflammatory diseases is in Phase I clinical trials. DV230-Nanoparticle is a second generation adjuvant. DV230-Nanoparticle is in preclinical stage.